Differences in the need for adalimumab dose optimization between Crohn's disease and ulcerative colitis.

David Olivares Cristina Alba Irene Pérez Enciso Valentín Roales Enrique Rey Carlos Taxonera

Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva (2020)

UC patients more frequently required adalimumab dose escalation than CD patients. UC patients required optimization earlier than CD patients. More CD patients than UC patients can be dose de-escalated later on during treatment.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
rheumatoid arthritis
randomized controlled trial
clinical trial
ulcerative colitis
open label